Semi-annual Report for 2026
Filed with SSE · · 167 pages · Chinese
Shandong Buchang Pharmaceuticals Co., Ltd. on 6ix
Earlier from Shandong Buchang Pharmaceuticals
- Announcement on Progress of Proposed Capital Increase to Controlled Subsidiary
- Announcement on Signing of Supplementary Agreement to (Entrusted) Technical Service Contract by a Controlled Subsidiary
- Announcement on Completion of Industrial and Commercial Registration Change by the Controlled Subsidiary
- Announcement on Receipt of Acceptance Notice for Drug Clinical Trial by Controlled Subsidiary
- Announcement on Change of Legal Representative of Controlled Subsidiary
Later from Shandong Buchang Pharmaceuticals
- Announcement on Obtaining Drug Registration Certificate by Wholly‑owned Subsidiary
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Resolutions of the 56th Meeting of the 5th Board of Directors
- (603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Change of Legal Representative of Controlled Subsidiary
- (603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Proposed Capital Increase in Controlled Subsidiary
Follow Shandong Buchang Pharmaceuticals into a list and get an email when it puts out news.
Follow Shandong Buchang Pharmaceuticals